These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33179214)

  • 1. Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients.
    Cho A; Untersteiner H; Hirschmann D; Fitschek F; Dorfer C; Rössler K; Zöchbauer-Müller S; Gatterbauer B; Hochmair MJ; Frischer JM
    J Neurooncol; 2021 Jan; 151(2):257-265. PubMed ID: 33179214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Non-Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy.
    Cho A; Kranawetter B; Untersteiner H; Khalaveh F; Dorfer C; Rössler K; Zöchbauer-Müller S; Gatterbauer B; Hochmair MJ; Frischer JM
    World Neurosurg; 2021 Jul; 151():e324-e331. PubMed ID: 33878466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor.
    Cho A; Untersteiner H; Fitschek F; Khalaveh F; Pruckner P; Pavo N; Rössler K; Dorfer C; Gatterbauer B; Höller C; Schmidinger M; Frischer JM
    J Neurooncol; 2021 Jul; 153(3):497-505. PubMed ID: 34148164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NLR, MLR, and PLR are adverse prognostic variables for sleeve lobectomy within non-small cell lung cancer.
    Han R; Zhang F; Hong Q; Visar D; Zhan C; Zhao C; Wang F; Zhang S; Li F; Li J; Mu J
    Thorac Cancer; 2024 Aug; 15(24):1792-1804. PubMed ID: 39034535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
    Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
    J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence and prognostic value of systemic inflammation in good performance status patients with advanced, inoperable non-small cell lung cancer receiving palliative radiotherapy: Comparison of composite ratios and cumulative scores.
    McGovern J; O'Rourke F; Will S; Nguyen HTN; Cranfield E; Maseland C; MacLeod N; Maclay JD; Laird BJ; Dolan RD; McMillan DC
    Cancer Med; 2024 Aug; 13(16):e70139. PubMed ID: 39164973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
    Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
    Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
    Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
    Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases.
    Li A; Mu X; He K; Wang P; Wang D; Liu C; Yu J
    Future Oncol; 2020 Oct; 16(30):2433-2444. PubMed ID: 32664750
    [No Abstract]   [Full Text] [Related]  

  • 13. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
    Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
    Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases.
    Starzer AM; Steindl A; Mair MJ; Deischinger C; Simonovska A; Widhalm G; Gatterbauer B; Dieckmann K; Heller G; Preusser M; Berghoff AS
    Br J Cancer; 2021 Mar; 124(7):1294-1300. PubMed ID: 33473170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.
    Shin SM; Cooper BT; Chachoua A; Butler J; Donahue B; Silverman JS; Kondziolka D
    J Neurooncol; 2016 Feb; 126(3):483-91. PubMed ID: 26520640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
    BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma.
    Feng X; Li L; Wu J; Zhang L; Sun Z; Li X; Wang X; Yu H; Chang Y; Wu X; Zhou Z; Wang G; Li W; Li Z; Zhang X; Zhang M
    Oncologist; 2019 Nov; 24(11):e1123-e1131. PubMed ID: 30952822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer.
    Ni XF; Wu J; Ji M; Shao YJ; Xu B; Jiang JT; Wu CP
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):402-409. PubMed ID: 30178541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.